Search results for "AGENTS"

showing 10 items of 7330 documents

Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial.

2002

Deferiprone has been suggested as an effective oral chelation therapy for thalassemia major. To assess its clinical efficacy, we compared deferiprone with deferoxamine in a large multicenter randomized clinical trial. One-hundred forty-four consecutive patients with thalassemia major and serum ferritin between 1500 and 3000 ng/ml were randomly assigned to deferiprone (75 mg/kg/day) (n = 71) or deferoxamine (50 mg/kg/day) (n = 73) for 1 year. The main measure of efficacy was the reduction of serum ferritin. Liver and heart iron contents were assessed by magnetic resonance. Liver iron content and fibrosis stage variations were assessed on liver biopsy by the Ishak score in all patients willin…

AdultLiver CirrhosisMalemedicine.medical_specialtyIron OverloadAdolescentPyridonesThalassemiaDeferoxamineIron Chelating AgentsGastroenterologylaw.inventionchemistry.chemical_compoundLeukocytopeniaRandomized controlled triallawInternal medicinemedicineHumansDeferiproneChelation therapyMolecular Biologymedicine.diagnostic_testbusiness.industrybeta-ThalassemiaCell BiologyHematologymedicine.diseaseIshak ScoreSurgeryDeferoxamineTreatment OutcomechemistryTherapeutic EquivalencyLiver biopsyFerritinsMolecular MedicineFemaleDeferipronebusinessmedicine.drugBlood cells, moleculesdiseases
researchProduct

Hepatitis C virus genotypes: distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe

2001

The aim of this study was to evaluate the distribution and clinical significance of hepatitis C virus (HCV) genotypes in European patients with compensated cirrhosis due to hepatitis C (Child class A) seen at tertiary referral centres. HCV genotypes were determined by genotype-specific primer PCR in 255 stored serum samples obtained from cirrhotics followed for a median period of 7 years. Inclusion criteria were biopsy-proven cirrhosis, absence of complications of cirrhosis and exclusion of all other potential causes of chronic liver disease. The proportion of patients with types 1b, 2, 3a, 1a, 4 and 5 were 69%, 19%, 6%, 5%, 0.5% and 0.5%, respectively. Kaplan-Meier 5-year risk of hepatocel…

AdultLiver CirrhosisMalemedicine.medical_specialtyPathologyCirrhosisHepacivirusHepatitis C virusHepacivirusAntibodies ViralChronic liver diseasemedicine.disease_causeAntiviral AgentsGastroenterologyDisease-Free SurvivalStatistics NonparametricSex FactorsSDG 3 - Good Health and Well-beingVirologyInternal medicineHumansMedicineDecompensationLongitudinal StudiesAgedProportional Hazards ModelsHepatologybiologybusiness.industryAge FactorsInterferon-alphaTransfusion ReactionHepatitis CMiddle Agedmedicine.diseasebiology.organism_classificationHepatitis CEuropeTreatment OutcomeInfectious DiseasesRelative riskHepatocellular carcinomaRNA ViralFemalebusiness
researchProduct

Predicting Mortality Risk in Patients With Compensated HCV-Induced Cirrhosis: A Long-Term Prospective Study

2009

OBJECTIVES: The identification of prognostic factors associated with mortality is crucial in any clinical setting. METHODS: We enrolled in a prospective study 352 patients with compensated hepatitis C virus (HCV)-induced cirrhosis, consecutively observed between 1989 and 1992. At entry, patients underwent upper endoscopy to detect esophageal varices, and were then surveilled by serial clinical and ultrasonographic examination. The model for end-stage liver disease (MELD) score was calculated with information collected at enrollment. Baseline predictors and intercurrent events associated with mortality were assessed using the Cox regression model. RESULTS: During a median follow-up of 14.4 y…

AdultLiver CirrhosisMalemedicine.medical_specialtyTime FactorsCirrhosisBiopsy Fine-NeedleKaplan-Meier EstimateEsophageal and Gastric VaricesAntiviral AgentsRisk AssessmentSeverity of Illness IndexGastroenterologyCohort StudiesPredictive Value of TestsCause of DeathInternal medicineEpidemiologyConfidence IntervalsmedicineHumansProspective StudiesRisk factorProspective cohort studyAgedProbabilityProportional Hazards ModelsCause of deathSettore MED/12 - GastroenterologiaHepatologybusiness.industryGastroenterologyInterferon-alphavirus diseasesHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseImmunohistochemistrySurvival Analysisliver cirrhosis natural historyDisease ProgressionFemalebusinessRisk assessmentLiver FailureFollow-Up StudiesCohort studyThe American Journal of Gastroenterology
researchProduct

Predictors of mortality in patients under treatment for chronic hepatitis B in Ethiopia: a prospective cohort study

2019

Abstract Background Antiviral treatment for chronic hepatitis B (CHB) is largely unavailable in sub-Saharan Africa; hence, little is known about the prognosis after initiating treatment in African CHB patients. In this study we aimed to assess predictors of mortality in one of the largest CHB cohorts in sub-Saharan Africa. Methods Two-hundred-and-seventy-six CHB patients who started treatment with tenofovir disoproxil fumarate at a public hospital in Ethiopia between March 18, 2015, and August 1, 2017, were included in this analysis. Patients were followed up until October 1, 2017, and deaths were ascertained through hospital records and telephone interview with relatives. Decompensated cir…

AdultLiver CirrhosisMalemedicine.medical_specialtyTime FactorsSurvivalAdolescentEpidemiologyPhysical examinationAntiviral therapyAntiviral AgentsBody Mass Index03 medical and health sciencesYoung Adult0302 clinical medicineHepatitis B ChronicInterquartile rangeRisk FactorsInternal medicineEpidemiologyMedicineHumansProspective Studieslcsh:RC799-869Prospective cohort studyTenofovirProportional Hazards Modelsmedicine.diagnostic_testbusiness.industryHazard ratioGastroenterologyAge FactorsGeneral MedicineHepatitis BHepatologyMiddle Agedmedicine.diseaseHepatitis BResource-limited settingsSurvival RateVDP::Medisinske Fag: 700::Helsefag: 800030220 oncology & carcinogenesislcsh:Diseases of the digestive system. Gastroenterology030211 gastroenterology & hepatologyFemaleEthiopiabusinessBody mass indexResearch Article
researchProduct

IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus …

2012

Background. Polymorphisms in the interleukin-28B are important determinants in the spontaneous and drug-induced control of hepatitis C virus infection. Design and Methods. We assessed the association of rs8099917 and rs12979860 polymorphisms with spontaneous viral clearance, severity of liver fibrosis, and response to interferon-monotherapy in 245 Thalassemia Major patients with Hepatitis C Virus infection. Results. Ninety-eight patients (40%) had a spontaneous viral clearance, while 147 patients (60%) developed a chronic infection. Spontaneous viral clearance was more frequent among patients with the T/T genotype of rs8099917 polymorphism (OR 2.130; p=0.008) or C/C genotype of rs12979860 p…

AdultLiver CirrhosisMalethlassemia hepatitis CInterferon InducersAdolescentHepacivirusHepatitis C virusAlpha interferonHepacivirusAdolescent; Adult; Antibodies Viral; Antiviral Agents; Cohort Studies; Female; Follow-Up Studies; Hepacivirus; Hepatitis C Chronic; Humans; Interferon Inducers; Interferon-alpha; Interleukins; Liver Cirrhosis; Male; Polymorphism Single Nucleotide; Prognosis; Viral Load; Young Adult; beta-Thalassemiamedicine.disease_causeAntibodies ViralAntiviral AgentsPolymorphism Single NucleotideCohort StudiesYoung AdultGenotypemedicineHumansInterferon inducerbiologymedicine.diagnostic_testInterleukinsbeta-ThalassemiaInterferon-alphaHematologyHepatitis CHepatitis C ChronicViral Loadbiology.organism_classificationmedicine.diseasePrognosisLiver biopsyImmunologyFemaleInterferonsOriginal Articles and Brief ReportsViral loadFollow-Up Studies
researchProduct

Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease

2022

Abstract Objective To compare clinical features and treatments of patients with systemic JIA (sIJA) and adult-onset Still’s disease (AOSD). Methods The clinical charts of consecutive patients with sJIA by International League of Association of Rheumatology criteria or AOSD by Yamaguchi criteria were reviewed. Patients were seen at a large paediatric rheumatology referral centre or at 10 adult rheumatology academic centres. Data collected included clinical manifestations, inflammation biomarkers, systemic score, macrophage activation syndrome (MAS), parenchymal lung disease, disease course, disability, death and medications administered. Results A total of 166 patients (median age at diagnos…

AdultLung DiseasesBiological ProductsMacrophage Activation SyndromeArthritis JuvenileSystemic juvenile idiopathic arthritis; adult-onset Still’s diseaseRheumatologyAdrenal Cortex HormonesSystemic juvenile idiopathic arthritisAntirheumatic AgentsFerritinsPrevalenceSystemic juvenile idiopathic arthritiHumansadult-onset Still’s diseasePharmacology (medical)ChildStill's Disease Adult-OnsetBiomarkersAcute-Phase Proteins
researchProduct

The impact of virus population diversity on the dynamics of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients

2017

Mixed cytomegalovirus (CMV) infections are associated with delayed viral clearance in solid organ transplant recipients. We investigated whether this could be extrapolated to allogeneic stem cell transplant (allo-SCT) recipients. A total of 48 plasma specimens, obtained during 29 episodes of active CMV infection in 25 non-consecutive allo-SCT patients, were analysed. Baseline blood specimens, drawn shortly prior to the inception of pre-emptive antiviral therapy (pre-treatment specimen; n=29), as well as follow-up samples obtained either after the initiation of antiviral therapy (post-treatment specimen; n=15) or during recurrent episodes (n=4) were analysed. Plasma CMV DNA loads were quanti…

AdultMale0301 basic medicine030106 microbiologyCytomegalovirusBiologymedicine.disease_causeAntiviral AgentsVirus03 medical and health sciencesVirologyGenotypemedicineHumansTransplantation HomologousGenotypingAgedBase SequenceGenetic VariationHigh-Throughput Nucleotide Sequencingvirus diseasesCytomegalovirusSequence Analysis DNACmv dnaemiaMiddle AgedViral LoadVirologyHypervariable region030104 developmental biologyCytomegalovirus InfectionsDNA ViralImmunologyFemalePopulation diversityStem cellStem Cell TransplantationJournal of General Virology
researchProduct

Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood

2015

Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood

AdultMale0301 basic medicineAdolescent030106 microbiologyCytomegalovirusVirus ReplicationAntiviral AgentsYoung Adult03 medical and health sciences0302 clinical medicineHumansTransplantation HomologousMedicineDoubling timeProgenitor cellGanciclovirAgedTransplantationbusiness.industryHematopoietic Stem Cell TransplantationAntiviral therapyHematologyMiddle Agedmedicine.diseaseTransplantationGraft-versus-host diseaseCytomegalovirus InfectionsDNA ViralImmunologyFemaleStem cellbusiness030215 immunologyBone Marrow Transplantation
researchProduct

Maternal diet shapes the breast milk microbiota composition and diversity: impact of mode of delivery and antibiotic exposure

2020

BACKGROUND: Breast milk is a complex biofluid that provides nutrients and bioactive agents, including bacteria, for the development of the infant gut microbiota. However, the impact of maternal diet and other factors, such as mode of delivery and antibiotic exposure, on the breast milk microbiota has yet to be understood. OBJECTIVES: This study aimed to examine the association between maternal diet and breast milk microbiota and to ascertain the potential role of mode of delivery and antibiotic exposure. METHODS: In a cross-sectional study of the MAMI cohort, breast milk microbiota profiling was assessed in 120 samples from healthy mothers by 16S rRNA gene sequencing. Maternal dietary infor…

AdultMale0301 basic medicineBreast milkNutrition and Diseasemedicine.drug_class030106 microbiologyAntibioticsBreastfeedingMedicine (miscellaneous)PhysiologyGut floraBreast milkPlant proteinCohort StudiesAnimal proteinAcademicSubjects/MED0006003 medical and health sciencesfluids and secretionsplant proteinLactobacillusmedicineHumansmaternal dietMaternal dietMicrobiomeBifidobacterium2. Zero hungerNutrition and DieteticsBacteriaMilk HumanbiologyMicrobiotaInfant Newbornfood and beveragesInfantbiology.organism_classificationAnti-Bacterial AgentsDiet3. Good healthCross-Sectional Studies030104 developmental biologyPlant proteinAcademicSubjects/SCI00960breast milkFemaleanimal protein
researchProduct

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractor…

2018

AbstractPurpose:Here, we report results of the first phase I study of erdafitinib, a potent, oral pan-FGFR inhibitor.Patients and Methods:Patients age ≥18 years with advanced solid tumors for which standard antineoplastic therapy was no longer effective were enrolled (NCT01703481). Parts 2 to 4 employed molecular screening for activating FGFR genomic alterations. In patients with such alterations, two selected doses/schedules identified during part 1 dose-escalation [9 mg once daily and 10 mg intermittently (7 days on/7 days off), as previously published (Tabernero JCO 2015;33:3401-8)] were tested.Results:The study included 187 patients. The most common treatment-related adverse events were…

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyAdministration OralAntineoplastic AgentsDrug resistanceGastroenterologyYoung Adult03 medical and health sciencesHyperphosphatemia0302 clinical medicineRefractoryErdafitinibNeoplasmsQuinoxalinesInternal medicinemedicineHumansNeoplasmDosingAdverse effectProtein Kinase InhibitorsAgedNeoplasm StagingAged 80 and overbusiness.industryGenetic VariationMiddle AgedPrognosismedicine.diseaseReceptors Fibroblast Growth FactorTreatment Outcome030104 developmental biologyOncologyTolerabilityDrug Resistance Neoplasm030220 oncology & carcinogenesisRetreatmentPyrazolesFemalebusinessClinical Cancer Research
researchProduct